Fosamprenavir - Vertex Pharmaceuticals/GSK
Alternative Names: 433908; 908; GW-433908; Lexiva; Telzir; VX-175Latest Information Update: 05 Nov 2023
At a glance
- Originator Vertex Pharmaceuticals
- Developer GlaxoSmithKline; GSK; Vertex Pharmaceuticals
- Class Antiretrovirals; Carbamates; Phosphoric acid esters; Small molecules; Sulfonamides
- Mechanism of Action HIV protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed HIV infections
Most Recent Events
- 11 Jul 2019 Discontinued - Phase-II for HIV infections (In adolescents, In children) in Romania, Spain, South Africa, Russia, Canada, Belgium, USA (PO) (NDR batch #16)
- 11 Jul 2019 Discontinued - Phase-II for HIV infections (In infants) in South Africa, Russia, Portugal, Latin America, USA (PO) (NDR batch #16)
- 03 Sep 2015 Fosamprenavir is still in phase II trials for HIV infections (In infants) in the USA, Latin America, Russia, Portugal and South Africa